B. Nebiyou Bekele - Concepedia

Author

B. Nebiyou Bekele

The University of Texas MD Anderson Cancer Center

Also Known As

B N Bekele, B Nebiyou Bekele, B. Bekele, B. N. BEKELE, B. N. Bekele, B. Nebiyou Bekele, B.N. Bekele, BN Bekele, Bekele, B. Nebiyou, Benjamin Bekele

210

Publications

13.4K

Citations

H-Index

120

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center The University of Texas Southwestern Medical Center Applied Mathematics (United States)

About

B. Nebiyou Bekele is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	34	3.1K
2	Health Sciences	11	12	1.8K
3	Engineering	3	3	257
4	Public Health	3	3	85
5	Biomedical Engineering	1	1	101

B. Nebiyou Bekele

115

Publications

11.8K

Citations

H-Index

Page 1

	Year	Citations
Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents Matus Studeny, F. Marini, Jennifer L. Dembinski, JNCI Journal of the National Cancer Institute	2004	837
Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System Victor A. Levin, Luc Bidaut, Ping Hou, International Journal of Radiation OncologyBiologyPhysics Neuro-oncologyRadiation TherapyMedicineRadiation NecrosisBrain Injury	2010	708
<i>KRAS</i>Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Erminia Massarelli, Marileila Varella‐Garcia, Ximing Tang, Clinical Cancer Research	2007	598
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma Alicia Rivera, Christopher E. Pelloski, Mark R. Gilbert, Neuro-Oncology	2009	448
Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features Luisa M. Solis, Carmen Behrens, Wenli Dong, Clinical Cancer Research	2010	419
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia Farhad Ravandi, Jörge E. Cortes, Daniel M. Jones, Journal of Clinical Oncology Hematological MalignancyOncologyPhase I/ii StudyMixed-phenotype Acute LeukemiaAcute Myeloid Leukemia	2010	355
Examination of the Therapeutic Potential of Delta-24-RGD in Brain Tumor Stem Cells: Role of Autophagic Cell Death Hong Jiang, Candelaria Gomez‐Manzano, Hiroshi Aoki, JNCI Journal of the National Cancer Institute Therapeutic PotentialCell TherapyImmunologyViral PathogenesisCell Death	2007	278
<i>EGFR</i> Tyrosine Kinase Domain Mutations Are Detected in Histologically Normal Respiratory Epithelium in Lung Cancer Patients Ximing Tang, Hisayuki Shigematsu, B. Nebiyou Bekele, Cancer Research	2005	270
A modified toxicity probability interval method for dose-finding trials Yuan Ji, Ping Liu, Yisheng Li, Clinical Trials	2010	263
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes Peter F. Thall, J. Kyle Wathen, B. Nebiyou Bekele, Statistics in Medicine	2003	198

Page 1